Grimm, M., Grün, B., Niegisch, G., Pichler, M., Roghmann, F. B. G., Schmitz-Dräger, B. J., . . . Zengerling, F. H. (2023). Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): A multicentre, single-arm, phase 2 trial. The lancet. Oncology, 24(4), . https://doi.org/10.1016/S1470-2045(23)00053-0
Chicago-Zitierstil (17. Ausg.)Grimm, Marc-Oliver, et al. "Tailored Immunotherapy Approach with Nivolumab with or Without Ipilimumab in Patients with Advanced Transitional Cell Carcinoma After Platinum-based Chemotherapy (TITAN-TCC): A Multicentre, Single-arm, Phase 2 Trial." The Lancet. Oncology 24, no. 4 (2023). https://doi.org/10.1016/S1470-2045(23)00053-0.
MLA-Zitierstil (9. Ausg.)Grimm, Marc-Oliver, et al. "Tailored Immunotherapy Approach with Nivolumab with or Without Ipilimumab in Patients with Advanced Transitional Cell Carcinoma After Platinum-based Chemotherapy (TITAN-TCC): A Multicentre, Single-arm, Phase 2 Trial." The Lancet. Oncology, vol. 24, no. 4, 2023, https://doi.org/10.1016/S1470-2045(23)00053-0.